Attovia Therapeutics (NASDAQ:ATTO) Announces Earnings Results, Misses Expectations By $0.02 EPS

Attovia Therapeutics (NASDAQ:ATTO) announced its earnings results on Monday. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02), Zacks reports.

Attovia Therapeutics Price Performance

Shares of NASDAQ ATTO traded up $0.69 during trading on Monday, hitting $15.96. 325,446 shares of the company traded hands, compared to its average volume of 350,522. The company has a market cap of $728.57 million and a price-to-earnings ratio of -3.27. The stock has a 50-day moving average of $18.06. Attovia Therapeutics has a 1 year low of $12.94 and a 1 year high of $28.00.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ATTO shares. Zacks Research raised Attovia Therapeutics to a “hold” rating in a report on Friday, September 4th. Leerink Partners initiated coverage on Attovia Therapeutics in a research note on Monday, August 31st. They set an “outperform” rating and a $52.00 price objective on the stock. Citigroup initiated coverage on Attovia Therapeutics in a research note on Monday, August 31st. They set a “buy” rating and a $30.00 price objective on the stock. Morgan Stanley assumed coverage on Attovia Therapeutics in a research report on Monday, August 31st. They set an “overweight” rating and a $39.00 price objective for the company. Finally, Lifesci Capital initiated coverage on shares of Attovia Therapeutics in a research report on Monday, August 31st. They issued an “outperform” rating and a $45.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $42.20.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. The company is working to address conditions in which existing treatments may not provide adequate efficacy, durability, or convenience.

Attovia uses its proprietary antibody-engineering and drug-development capabilities to discover and advance biologic therapies designed to modulate disease-driving immune pathways.